Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy

ClinicalTrials.gov ID: NCT07823322

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07823322. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.

Study identification

NCT ID
NCT07823322
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
40 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2026 (Estimated)
Primary completion
May 14, 2029 (Estimated)
Completion
May 14, 2029 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2029

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010 Not yet recruiting
Oncura Health Glendale California 91204 Not yet recruiting
City of Hope Medical Center Irvine California 92618 Not yet recruiting
City of Hope - Chicago Cancer Center Zion Illinois 60099 Not yet recruiting
Maryland Oncology Hematology P.A. Rockville Maryland 20850 Not yet recruiting
The University of North Carolina At Chapel Hill Chapel Hill North Carolina 27514 Not yet recruiting
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 Not yet recruiting
Tennessee Oncology, Pllc Nashville Tennessee 37203 Not yet recruiting
Vanderbilt University Medical Center Nashville Tennessee 37232 Not yet recruiting
Texas Oncology Northeast Location Flower Mound Texas 75028 Not yet recruiting
Md Anderson Cancer Center Houston Texas 77030 Not yet recruiting
Texas Oncology Webster Texas 77598 Not yet recruiting
Virginia Cancer Specialists, Pc Fairfax Virginia 22031 Not yet recruiting
Fred Hutchinson Cancer Center Seattle Washington 98109 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07823322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.